{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-003159","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.069315+00:00","generated_at":"2026-06-26T00:50:32.404560+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Compass reports CTX-009 42% ORR in biliary tract cancers; to start U.S. Phase 2 in Q3 2022","bullets":["CTX-009 + paclitaxel achieved 42% ORR (10 PRs) out of 24 patients with advanced biliary tract cancers.","Clinical benefit rate 92% (22/24 patients had PR or stable disease); responses across all four BTC subtypes.","Safety consistent with Phase 1: common AEs included hypertension (50%) and neutropenia (54.2%); manageable.","Plans to initiate Stage 2 of Phase 2 study in the U.S. in Q3 2022, following Simon Two-Stage design criteria met."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-003159","json":"https://secwatch.observer/filing/0001171843-22-003159.json","markdown":"https://secwatch.observer/filing/0001171843-22-003159.md","text":"https://secwatch.observer/filing/0001171843-22-003159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322003159/0001171843-22-003159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322003159/f8k_050422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:50:32.404560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}